AID in aging and autoimmune diseases

Autoimmunity

Volumn 46, Issue 2, 2013, Pages 168-175

  Frasca, Daniela ^a   Andrisani, Gianluca ^b   Diaz, Alain ^a   Felice, Carla ^b   Guidi, Luisa ^b   Blomberg, Bonnie B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aging; AID (activation induced cytidine deaminase); B lymphocytes; IBD (Inflammatory Bowel Disease); P2009 (pandemic 2009) influenza vaccine

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

2009 H1N1 INFLUENZA; ADULT; AGED; AGING; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; ENTERITIS; FEMALE; GERIATRIC PATIENT; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL;

ADULT; AGE FACTORS; AGED; AGING; ANTIBODIES, VIRAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CYTIDINE DEAMINASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED;

EID: 84873696145     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.750300     Document Type: Article

References (56)

1. Okazaki, I. M., K. Kinoshita, M. Muramatsu, K. Yoshikawa, and T. Honjo. 2002. The AID enzyme induces class switch recombination in fibroblasts. Nature 416: 340-345
2. Yoshikawa, K., I. M. Okazaki, T. Eto, et al. 2002. AID enzymeinduced hypermutation in an actively transcribed gene in fibroblasts. Science 296: 2033-2036
3. Muramatsu, M., K. Kinoshita, S. Fagarasan, et al. 2000. Class switch recombination and hypermutation require activationinduced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563
4. Revy, P., T. Muto, Y. Levy, et al. 2000. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102: 565-575
5. Stavnezer, J., J. E. Guikema, and C. E. Schrader. 2008. Mechanism and regulation of class switch recombination. Annu. Rev. Immunol. 26: 261-292
6. Pone, E. J., H. Zan, J. Zhang, A. Al-Qahtani, Z. Xu, and P. Casali. 2010. Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Crit. Rev. Immunol. 30: 1-29
7. Frasca, D., and B. B. Blomberg. 2011. Aging affects human B cell responses. J. Clin. Immunol. 31: 430-435
8. Frasca, D., A. Diaz, M. Romero, et al. 2010. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 28: 8077-8084
9. Frasca, D., A. Diaz, M. Romero, et al. 2012. Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int. Immunol. 24: 175-182
10. Frasca, D., A. M. Landin, S. C. Lechner, et al. 2008. Aging down-regulates the transcription factor E2A, activationinduced cytidine deaminase, and Ig class switch in human B cells. J. Immunol. 180: 5283-5290
11. Muramatsu, M., H. Nagaoka, R. Shinkura, N. A Begum, and T. Honjo. 2007. Discovery of activation-induced cytidine deaminase, the engraver of antibody memory. Adv. Immunol. 94: 1-36
12. Rada, C., G. T. Williams, H. Nilsen, et al. 2002. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Curr. Biol. 12: 1748-1755
13. Levy, J., T. Espanol-Boren, C. Thomas, et al. 1997. Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr. 131: 47-54
14. Lougaris, V., R. Badolato, S. Ferrari, and A. Plebani. 2005. Hyper immunoglobulinMsyndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol. Rev. 203: 48-66
15. Durandy, A. 2002. Hyper-IgM syndromes: a model for studying the regulation of class switch recombination and somatic hypermutation generation. Biochem. Soc. Trans. 30: 815-818
16. Ferrari, S., S. Giliani, A. Insalaco, et al. 2001. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc. Natl. Acad. Sci. USA 98: 12614-12619
17. Imai, K., Y. Zhu, P. Revy, et al. 2005. Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. Clin. Immunol. 115: 277-285
18. Imai, K., G. Slupphaug, W. I. Lee, et al. 2003. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat. Immunol. 4: 1023-1028
19. Meyers, G., Y. S. Ng, J. M. Bannock, et al. 2011. Activationinduced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proc. Natl. Acad. Sci. USA 108: 11554-11559
20. Gronwall, C., J. Vas, and G. J. Silverman. 2012. Protective roles of natural IgM antibodies. Front. Immunol. 3: 66
21. Jiang, C., J. Foley, N. Clayton, et al. 2007. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J. Immunol. 178: 7422-7431
22. Jiang, C., M. L. Zhao, R. M. Scearce, and M. Diaz. 2011. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis. Arthritis Rheum. 63: 1086-1096
23. Mannoor, K., A. Matejuk, Y. Xu, M. Beardall, and C. Chen. 2012. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. J. Immunol. 188: 3628-3638
24. Frasca, D., E. Van der Put, R. L. Riley, and B. B. Blomberg. 2004. Reduced Ig class switch in aged mice correlates with decreased E47 and activation-induced cytidine deaminase. J. Immunol. 172: 2155-2162
25. Gibson, K. L., Y. C. Wu, Y. Barnett, et al. 2009. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 8: 18-25
26. Quong,M.W.,W. J. Romanow, and C. Murre. 2002. E protein function in lymphocyte development. Annu. Rev. Immunol. 20: 301-322
27. Sayegh, C. E., M. W. Quong, Y. Agata, and C. Murre. 2003. E-proteins directly regulate expression of activation-induced deaminase in mature B cells. Nat. Immunol. 4: 586-593
28. Ben-Horin, S., I. Goldstein, E. Fudim, et al. 2009. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut 58: 396-403
29. Poppe, D., I. Tiede, G. Fritz, et al. 2006. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176: 640-651
30. Johnston, A., J. E. Gudjonsson, H. Sigmundsdottir, B. R. Ludviksson, and H. Valdimarsson. 2005. The antiinflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin. Immunol. 114: 154-163
31. Tracey, D., L. Klareskog, E. H. Sasso, J. G. Salfeld, and P. P. Tak. 2008. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117: 244-279
32. Deutsch, D. E., A. D. Olson, S. Kraker, and C. J. Dickinson. 1995. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J. Pediatr. Gastroenterol. Nutr. 20: 351-353
33. Korelitz, B. I., S. R. Fuller, J. I.Warman, and M. D. Goldberg. 1999. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am. J. Gastroenterol. 94: 424-426
34. Ferrucci, L., A. Corsi, F. Lauretani, et al. 2005. The origins of age-related proinflammatory state. Blood 105: 2294-2299
35. Franceschi, C., M. Capri,D. Monti, et al. 2007. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans.Mech. Ageing Dev. 128: 92-105
36. Franceschi, C., S. Valensin, M. Bonafe, et al. 2000. The network and the remodeling theories of aging: historical background and new perspectives. Exp. Gerontol. 35: 879-896
37. Harris, T. B., L. Ferrucci, R. P. Tracy, et al. 1999. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106: 506-512
38. Wikby, A., B. O. Nilsson, R. Forsey, et al. 2006. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech. Ageing Dev. 127: 695-704
39. Andrisani, G., D. Frasca, M. Romero, et al. 2012. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: Effects of combined therapy with immunosuppressants. J. Crohns Colitis, in press
40. Murasko, D. M., E. D. Bernstein, E. M. Gardner, et al. 2002. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol. 37: 427-439
41. Skowronski, D. M., S. A. Tweed, and G. De Serres. 2008. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J. Infect. Dis. 197: 490-502
42. Ito, T., Y. Suzuki, L. Mitnaul, et al. 1997. Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology 227: 493-499
43. Frasca, D., A. Diaz, M. Romero, A. M. Landin, and B. B. Blomberg. 2011. Age effects on B cells and humoral immunity in humans. Ageing Res. Rev. 10: 330-335
44. Cullen, G., C. Bader, J. R. Korzenik, and B. E. Sands. 2012. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 61: 385-391
45. Gelinck, L. B., A. E. van der Bijl, W. E. Beyer, et al. 2008. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis. 67: 713-716
46. Molnar, T., K. Farkas, I. Jankovics, et al. 2011. Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy. Am. J. Gastroenterol. 106: 370-372
47. Macdonald, T. T., and G. Monteleone. 2005. Immunity, inflammation, and allergy in the gut. Science 307: 1920-1925
48. ACIP 1993. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm. Rep. 42: 1-18
49. Rahier, J. F., Y. Yazdanpanah, N. Viget, S. Travis, and J. F. Colombel. 2010. Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 31: 5-10
50. Sands, B. E., C. Cuffari, J. Katz, et al. 2004. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10: 677-692
51. Melmed, G. Y., A. F. Ippoliti, K. A. Papadakis, et al. 2006. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am. J. Gastroenterol. 101: 1834-1840
52. Sambhara, S., and J. E. McElhaney. 2009. Immunosenescence and influenza vaccine efficacy. Curr. Top. Microbiol. Immunol. 333: 413-429
53. Zhou, X., and J. E. McElhaney. 2011. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine 29: 2169-2177
54. Noronha, A. M., Y. Liang, J. T. Hetzel, et al. 2009. Hyperactivated B cells in human inflammatory bowel disease. J. Leukoc. Biol. 86: 1007-1016
55. Lodes, M. J., Y. Cong, C. O. Elson, et al. 2004. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest. 113: 1296-1306
56. Frasca, D., M. Romero, A. Diaz, et al. 2012. A molecular mechanism for TNF-alpha-mediated downregulation of B cell responses. J. Immunol. 188: 279-286